Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tamaki, Shunsuke ^a,b   Mano, Toshiaki ^a,b   Sakata, Yasushi ^a   Ohtani, Tomohito ^a   Takeda, Yasuharu ^a   Kamimura, Daisuke ^b,c   Omori, Yosuke ^a,b   Tsukamoto, Yasumasa ^a,b   Ikeya, Yukitoshi ^a,d   Kawai, Mari ^a   Kumanogoh, Atsushi ^a   Hagihara, Keisuke ^a   Ishii, Ryohei ^e   Higashimori, Mitsuru ^e   Kaneko, Makoto ^e   Hasuwa, Hidetoshi ^b   Miwa, Takeshi ^b   Yamamoto, Kazuhiro ^f   Komuro, Issei ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; INTERLEUKIN 16; INTERLEUKIN 16 NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; LUNG WEIGHT; MACROPHAGE; MALE; MOUSE; MYOCARDIAL DISEASE; MYOCARDIAL STIFFNESS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TRANSGENIC MOUSE; UPREGULATION;

AGED; AGED, 80 AND OVER; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION; INTERLEUKIN-16; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MYOCARDIUM; RATS; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84880399011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068893     Document Type: Article

References (42)

1. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, et al. (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344-350.
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355: 260-269.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, et al. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251-259.
4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777-781.
5. Zile MR, Baicu CF, Gaasch WH, (2004) Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953-1959.
6. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, et al. (2002) Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82.
7. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, et al. (2000) Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 36: 2333-2338.
8. Anker SD, von Haehling S, (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90: 464-470.
9. Mann DL, (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998.
10. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, et al. (1998) Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97: 1136-1143.
11. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, et al. (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055-2059.
12. Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, et al. (2009) IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 297: H76-85.
13. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, et al. (2010) Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56: 225-231.
14. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, et al. (2011) Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 50: 248-256.
15. Wynn TA, (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524-529.
16. Berk BC, Fujiwara K, Lehoux S, (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575.
17. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, et al. (2004) AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 43: 686-691.
18. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, et al. (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4: 44-52.
19. Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, et al. (2000) Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 119: 972-982.
20. Skundric DS, Cai J, Cruikshank WW, Gveric D, (2006) Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation 3: 13.
21. Hessel EM, Cruikshank WW, Van Ark I, De Bie JJ, Van Esch B, et al. (1998) Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 160: 2998-3005.
22. McKee PA, Castelli WP, McNamara PM, Kannel WB, (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285: 1441-1446.
23. Takeda Y, Sakata Y, Higashimori M, Mano T, Nishio M, et al. (2009) Noninvasive assessment of wall distensibility with the evaluation of diastolic epicardial movement. J Card Fail 15: 68-77.
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463.
25. Lester SJ, Ryan EW, Schiller NB, Foster E, (1999) Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol 84: 829-832.
26. Ohtani T, Mohammed SF, Yamamoto K, Dunlay SM, Weston SA, et al. (2012) Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 33: 1742-1749.
27. Kamimura D, Ohtani T, Sakata Y, Mano T, Takeda Y, et al. (2012) Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J 33: 1408-1416.
28. Meagher C, Beilke J, Arreaza G, Mi QS, Chen W, et al. (2010) Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 59: 2862-2871.
29. Kimura N, Itoh S, Nakae S, Axtell RC, Velotta JB, et al. (2011) Interleukin-16 deficiency suppresses the development of chronic rejection in murine cardiac transplantation model. J Heart Lung Transplant 30: 1409-1417.
30. Terui T, Shimamoto Y, Yamane M, Kobirumaki F, Ohtsuki I, et al. (2010) Regulatory mechanism of length-dependent activation in skinned porcine ventricular muscle: role of thin filament cooperative activation in the Frank-Starling relation. J Gen Physiol 136: 469-482.
31. Ishii R, Higashimori M, Tadakuma K, Kaneko M, Tamaki S, et al. (2011) Balloon type elasticity sensing for left ventricle of small laboratory animal. Conf Proc IEEE Eng Med Biol Soc 2011: 904-907.
32. Ohtani T, Mano T, Hikoso S, Sakata Y, Nishio M, et al. (2009) Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. J Hypertens 27: 1074-1083.
33. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, et al. (2010) Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 299: H1328-1338.
34. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, et al. (1999) Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100: 2449-2454.
35. Doser TA, Turdi S, Thomas DP, Epstein PN, Li SY, et al. (2009) Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 119: 1941-1949.
36. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, et al. (2007) Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol 49: 972-981.
37. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA, (2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95: 637-644.
38. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, et al. (1994) Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 70: 286-294.
39. Cruikshank WW, Berman JS, Theodore AC, Bernardo J, (1987) Center DM (1987) Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol 138: 3817-3823.
40. Center DM, Cruikshank W (1982) Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 128: 2563-2568.
41. Cruikshank W, Little F, (2008) lnterleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol 28: 467-483.
42. Hermann E, Darcissac E, Idziorek T, Capron A, Bahr GM, (1999) Recombinant interleukin-16 selectively modulates surface receptor expression and cytokine release in macrophages and dendritic cells. Immunology 97: 241-248.